Table 4.
Randomized Controlled Trials Evaluating Conduction System Pacing Outcomes.
| Study | His-SYNC [88] | His-Alternative [89] | LEVEL-AT [90] | LBBP-RESYNC [91] |
|---|---|---|---|---|
| Year of Publication | 2019 | 2021 | 2022 | 2022 |
| Type of CSP | HBP | HBP | HBP, LBBP | LBBP |
| Number of Patients | 41 | 50 | 70 | 40 |
| Age | 64 ± 13 | 63.8 ± 9 | 65.7 ± 9 | 63.7 ± 11 |
| Mean LVEF (%) | 28 | 30 ± 6 | 27 ± 7 | 28.3 ± 5 |
| Follow-up (mon) | 6.2 | 6.0 | 6.0 | 6.0 |
| LBBB (%) | 85 | 100 | 60 | 100 |
| Baseline QRS Duration (ms) | 168 ± 18 | 165 ± 14 | 177 ± 21 | 174.6 ± 14 |
| ICM (%) | 65.0 | 20.0 | 31.4 | 0.0 |
| Threshold (V) | 1.7 | 2.4 ± 1.6 | 1.0 ± 0.4 | 0.82 ± 0.20 |
| Pulse Width (ms) | 1.0 | 1.0 | 0.6 ± 0.3 | 0.5 |
| Procedure Time (min) | NR | 137 ± 46 | 125 ± 35 | 129 ± 32 |
| Complications (%) | NR | 0 | 11.4% * | NR |
| Dislodgements (%) | 0 | 0 | 1 | 0 |
| Delta QRS duration (ms) | −28 | −34 | −53 ± 20 | −43 |
| Delta LVEF (%) | +9.1 | +16 ± 7 | +12.2 ± 9 | +5.6 |
| Delta LVESV (mL) | NR | −53 | −37 ± 59 | −25 |
| Delta LVAT (ms) | NR | NR | −28 ± 26 | 79.74 ± 9.94 † |
| Other Comments | No difference in CV hospitalization or death | --- | No difference in mortality or HFH | BNP favoured LBBP |
CSP = conduction system pacing; mon = months; ms = milliseconds; ICM = ischemic cardiomyopathy; V = volts; min = minutes; mL = milliliters; HBP = His bundle pacing; LBBP = left bundle branch pacing; NR = not reported; HFH = heart failure hospitalization; CV = cardiovascular; BNP = brain natriuretic peptide; * Requiring intervention; † Mean LVAT.